Articles tagged with Retinopathy
A UCI-led study demonstrates the therapeutic potential of base editing for treating inherited ocular diseases, restoring visual function to near-normal levels. The new CRISPR technology overcomes previous barriers, enabling precise and predictable correction of point mutations.
Researchers developed a new instrument to measure tiny light-evoked deformations in individual rods and cones, offering potential for earlier detection of retinal diseases. The system combines high-speed OCT imaging with adaptive optics technology to capture photoreceptor responses, paving the way for improved diagnosis and treatment.
A new AI-based device has been developed to help diagnose aggressive posterior retinopathy of prematurity (AP-ROP) in newborns. The study found that infants who developed AP-ROP were more premature and had lower birth weights, highlighting the need for early detection and monitoring.
Scientists discover enzyme arginase 1 plays protective role in retinal health by suppressing inflammation and promoting recovery. Administering pegylated arginase 1 reduces inflammation and subsequent damage following reperfusion injury, offering potential new treatment for neurovascular injury.
A new AI-powered algorithm has been developed to diagnose retinopathy of prematurity (ROP), a leading cause of childhood blindness, with an accuracy rate of 91% compared to 82% for human experts. The algorithm uses deep learning to analyze images of infant eyes and can help prevent blindness in more babies worldwide.
A machine learning algorithm diagnosed retinopathy of prematurity (ROP) with comparable or better accuracy than human experts, based on 5,511 images. The study aimed to improve diagnosis, which is currently highly subjective and variable.
A new study published in JAMA Ophthalmology suggests that telemedicine can accurately diagnose a rare cause of blindness in premature babies. The study found no significant difference between in-person and remote exams for diagnosing retinopathy of prematurity, which affects up to 16,000 US babies each year.
A new AI platform can diagnose two common retinal diseases and rate their severity with over 95% accuracy, as well as distinguish between viral and bacterial pneumonia. This technology has the potential to improve patient outcomes and increase access to care in remote areas.
A new gene therapy has shown significant improvements in vision for patients with Leber congenital amaurosis, a rare inherited retinal disease. The treatment, currently under FDA review, allows patients to navigate mazes and experience improved light sensitivity and peripheral vision.
A new study successfully uses a shortened version of the CEP290 gene to treat Leber congenital amaurosis type 10, a rare genetic disorder causing blindness. The treatment shows significant improvement in photoreceptor survival and function.
A new study published in Acta Paediatrica indicates that survival rates for babies born weighing 500g are alarmingly low. Short-term morbidity is prevalent among surviving infants, with retinopathy of prematurity and chronic lung disease being common issues.
Scientists developed an organ-on-a-chip model that mimics human retinal cells and vascular endothelial cells. The model replicates neovascularization in wet-type age-related macular degeneration, offering a potential alternative to animal models for disease modeling and drug screening.
Researchers found that preeclampsia in pregnant rats led to less severe retinopathy and normal retinal vascular development in offspring. The combination of preeclampsia and oxygen fluctuations reduced features of ROP. Growth factors needed for retina development came from the pups, not the mothers.
Katherine High discusses gene therapy progress for hemophilia and inherited retinal disorders, highlighting key scientific, regulatory, and commercial challenges. Her leadership in the field has been critical to its current success.
Researchers have identified a novel protein, Tmem135, that regulates retinal aging and causes age-dependent diseases like macular degeneration in mice. The study reveals that irregular levels of the protein lead to symptoms of macular degeneration.
A new study published in the Journal of AAPOS found a modest but significantly increased risk of retinopathy in very premature infants who received steroid treatment. The study analyzed data from 1,472 neonates and found that steroid-treated infants had a higher incidence of ROP than untreated infants.
Researchers have developed a new viral vector-based delivery system for retinal cells, aiming to treat visual impairments caused by age-related macular degeneration (AMD). The system uses highly photosensitive opsins to stimulate retinal cells and restore vision.
Researchers have demonstrated that retinal cells carry out key processing tasks, paving the way for improved retinal implants and potentially restoring vision to those with macular degeneration. This breakthrough could significantly improve artificial retinas and enhance the sight of thousands affected by age-related macular degeneration.
Robert E. Marc, a renowned vision scientist at the University of Utah, has been awarded the Paul Kayser International Award for his significant contributions to understanding vitreoretinal diseases and disorders. The award recognizes Marc's groundbreaking work on retinal mapping and neural pathways.
A study found that pre-term infants with severe retinopathy of prematurity are at a higher risk of developing non-visual disabilities, including motor impairment and cognitive impairment. These findings may help improve counseling for parents and selecting high-risk infants for long-term follow-up.
New research shows that vegetable oil fatty acids can increase plasma membrane fluidity in retina cells, reducing the risk of retinopathy and age-related macular degeneration. A diet rich in omega-3 fatty acids and olive oil may also contribute to preventing retina diseases.
Researchers found a higher risk of stroke in patients with mild and moderate/severe hypertensive retinopathy. The study suggests retinal imaging could provide additional information on stroke risk in people with high blood pressure.
Researchers discovered that horizontal cells, processing visual information, are crucial for maintaining photoreceptor cell integrity. Without Onecut1, the number of photoreceptors decreases, leading to potential retinal degradation and diseases like retinitis pigmentosa.
A randomized trial found targeting oxygen saturations of 85-89% compared to 91-95% had no significant effect on death or disability in extremely preterm infants at 18 months. The study included 1,201 infants with gestational ages of 23-27 weeks and monitored them until postmenstrual age of 36-40 weeks.
A Danish national cohort study found that cerebral damage and retinopathy of prematurity are independently associated with visual impairment in preschool children born extremely premature. The authors identified global developmental deficits, moderate to severe foveal abnormality, and ROP treatment as risk factors for VA loss.
Gene Signal's aganirsen shows promise in treating wet age-related macular degeneration and ischemic retinopathy by inhibiting neovascular growth. Clinical studies are scheduled to begin during the second quarter of 2012.
A study published in Neurology found that women with mild retinopathy had lower scores on cognitive tests and more brain damage than those without the condition. The researchers suggest that eye screening could be a simple way to identify people at risk of brain health issues.
Topical aganirsen shows efficacy equivalent to Lucentis in models of AMD and ischemic retinopathy, inhibiting neovascularization by blocking IRS-1. The study demonstrates a novel compound with excellent safety profile for treating retinal neovascular disease.
Researchers have successfully used induced pluripotent stem (iPS) cells to correct a genetic defect in gyrate atrophy, a rare blinding disorder. The study demonstrates the potential for iPS cells to repair damaged retinal pigment epithelium cells and restore vision.
A new study published in The New England Journal of Medicine found that intravitreal bevacizumab significantly reduces the recurrence rate of retinopathy of prematurity in premature infants. The drug therapy also appears to preserve vision better than conventional laser treatment, with no need for intubation and a faster recovery.
Researchers tested beta carotene's effects on retinitis pigmentosa, a cluster of hereditary disorders causing incurable blindness. One-third of patients showed improved visual function after taking the nutrient for 90 days, while two-thirds had no response.
A new clinical trial at The Children's Hospital at OU Medical Center aims to detect Retinopathy of Prematurity (ROP) in premature infants through a novel technique. If successful, the method could prevent blindness and save $1 million per child in lifetime support costs.
Researchers at Penn University successfully used gene therapy to restore retinal cone function and day vision in canines with inherited day blindness. The treatment was effective for younger dogs and held promise for future clinical trials.
Certain children with Type 1 retinopathy of prematurity benefit from early treatment, showing improved vision at age 6. In contrast, those with Type 2 disease do not see a significant benefit from early treatment at this age.
The American Academy of Ophthalmology affirms the effectiveness of current retinopathy of prematurity (ROP) diagnosis and treatment practices. Early treatment has been shown to improve visual acuity outcomes for these vulnerable infants, supporting ongoing ROP research.
Researchers at the University of Iowa have found a new inherited retinal disease affecting the macula, which is an area critical for central vision. The disease causes abnormal blood vessels to form, leading to swelling or scars that can blur parts of the visual field.
A Swedish study found that more pre-term infants surviving in neonatal intensive care units are experiencing vision problems due to retinopathy of prematurity, a condition involving abnormal blood vessel development in the retina. The incidence of this condition is higher in extremely preterm infants born before 27 weeks' gestation.
A team of researchers from the University of Florida and Harvard Medical School has discovered a protein called IGFBP-3 that may help prevent eye damage in premature babies. The protein activates stem cells and other reparative cells, which could stabilize existing blood vessels and prevent abnormal growth.
A study published in Neurology found that middle-aged individuals with a history of migraine and other headaches are more likely to develop retinopathy, which can lead to severe vision problems or blindness. The association was strongest among those with migraine headaches and aura.
A study published in Archives of Ophthalmology confirms the effectiveness of genetic testing in diagnosing complex retinal diseases. The research found that genetic testing confirmed a clinician's diagnosis in half of the tested cases, providing crucial information for healthcare professionals.
A new study found that 61% of chronic hepatitis C patients treated with Interferon developed asymptomatic retinopathy, including retinal hemorrhage and cotton-wool spots. The condition was associated with increased blood velocity and endothelial dysfunction, highlighting the importance of monitoring patients during treatment.
Wolfgang Drexler, a Professor at Cardiff University, is recognized for his development of Optical Coherence Tomography technique, leading to diagnosis of retinal diseases and cellular level resolution.
A study of 216 prematurely born children found reduced distance and near visual acuities compared to full-term children. Two percent were visually impaired, and 5.3% had low visual acuity after treatment for retinopathy of prematurity or cryotherapy.
A study of 326 children with severe malaria found that 61% had retinopathy, which was associated with higher death rates and prolonged coma. The researchers suggest that retinal signs may be related to cerebral pathophysiology in childhood CM.
Researchers found that mutations in the ABCR gene cause a wide range of eye problems, including Stargardt disease and retinitis pigmentosa. The study suggests that a single therapy designed to replace ABCR activity could alleviate or prevent retinal degeneration.